 |
  
|
  |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
U.S. News Progenics HIV Drug Gets Fast Track StatusFebruary 23, 2006 On Wednesday, Progenics Pharmaceuticals Inc. of Tarrytown, N.Y., announced that the Food and Drug Administration has granted fast-track status to its PRO 140 therapeutic for the treatment of HIV. The drug, which is now in early-stage trials, is a humanized monoclonal antibody directed against CCR5, a molecular portal that HIV uses to enter cells. Fast-track status streamlines the regulatory review process. The drug may also be considered for priority six-month review (instead of the standard 10-month review) and accelerated approval. Associated Press 02.22.2006  This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
|
 |
Email
Print-Friendly
Glossary
The Body: About The Body | Contact The Body | Content Policy | Content Providers | Advertise With Us | Site Map
Remedy Health Media: About Remedy Health Media | Contact Remedy Health Media | Terms of Use | Privacy Policy
The Body is a service of Remedy Health Media, LLC, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.
